Ironwood Pharmaceuticals traded at $11.92 this Thursday July 7th, increasing $0.05 or 0.42 percent since the previous trading session. Looking back, over the last four weeks, Ironwood Pharmaceuticals gained 1.41 percent. Over the last 12 months, its price fell by 3.09 percent. Looking ahead, we forecast Ironwood Pharmaceuticals to be priced at 11.22 by the end of this quarter and at 10.33 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
11.92
Daily Change
0.42%
Yearly
-3.09%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,932.00 70.00 1.81% 7.73%
Astellas Pharma 2,144.00 17.50 0.82% 14.93%
Acadia Pharmaceuticals 15.12 -0.15 -0.98% -36.92%
Agios Pharmaceuticals 25.35 -0.10 -0.39% -55.38%
Akebia Therapeutics 0.46 0.05 12.47% -86.39%
Almirall SA 10.62 0.01 0.09% -26.86%
Alnylam Pharmaceuticals 150.00 -0.73 -0.48% -13.09%
Amarin 1.59 0.03 1.60% -62.71%
Ardelyx 0.62 0.01 1.98% -92.12%
AstraZeneca 11,050.00 72.00 0.66% 28.65%
Astrazeneca 66.49 0.98 1.50% 11.26%
Bluebird Bio 4.82 -0.23 -4.55% -84.51%
Coherus Biosciences 8.88 0.34 3.98% -33.73%
Charles River Laboratories 226.01 3.29 1.48% -41.02%
Emergent BioSolutions 32.87 0.03 0.09% -46.58%
Esperion Therapeutics 6.68 -0.01 -0.13% -65.29%
Exact Sciences 43.80 0.51 1.18% -62.80%
Halozyme Therapeutics 47.07 0.32 0.68% 3.18%
Intercept Pharmaceuticals 13.85 -1.44 -9.42% -27.03%
Incyte Corp 80.77 1.05 1.32% -1.66%
Ironwood Pharmaceuticals 11.92 0.05 0.42% -3.09%
Karyopharm Therapeutics 5.24 0.02 0.38% -47.96%
Lexicon Pharmaceuticals 2.64 0.01 0.38% -32.13%
MacroGenics 3.50 0.08 2.34% -87.47%
Moderna Inc 169.26 9.70 6.08% -27.29%
Myriad Genetics 19.38 0.37 1.95% -39.53%
Puma Biotechnology 2.79 0.01 0.36% -66.22%
Pacira 59.07 1.41 2.44% 4.10%
PTC Therapeutics 43.62 0.71 1.65% -0.95%
Ultragenyx Pharmaceutical 64.70 1.32 2.07% -27.82%
Sarepta Therapeutics 75.97 0.23 0.30% 5.53%
Vanda Pharmaceuticals 11.69 0.19 1.65% -42.10%

Indexes Price Day Year
USND 11525 163.45 1.44% -20.84%
US2000 1763 35.12 2.03% -21.02%

Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company. The Company is focused on the development and commercialization of GI product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC). It operates in human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women suffering from IBS-C or CIC in the United States, and Mexico and to adult men and women suffering from IBS-C in Japan and China. Its linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries.